Identification of Possible Biomarkers in Cardiovascular Diseases

Authors

  • Bogdan-Ioan Coculescu “Cantacuzino” National Medico-Military Institute for Research and Development, Bucharest, Romania and Faculty of Medicine, “Titu Maiorescu” University, Bucharest, Romania
  • Gabi Valeriu Dincă Faculty of Medicine, “Titu Maiorescu” University, Bucharest, Romania
  • Gheorghe Manole Faculty of General Nursing, “Bioterra” University, Bucharest, Romania
  • Elena Claudia Coculescu Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

DOI:

https://doi.org/10.12974/2312-5411.2022.09.01

Keywords:

Cardiovascular diseases, Atherosclerosis, Risk biomarkers

Abstract

Currently, one of the major medical topics researched is the identification in the most diverse diseases, of new molecular biomarkers that would allow the establishment of a positive diagnosis, but also of the response to a certain established treatment (risk biomarkers). Prolonging the lifespan of individuals and increasing the frequency of heart failure from 1-2% in the adult population, regardless of age, to 10-12% in people over 70 explains the worldwide interest in identifying biomarkers and in this condition, regardless of etiology, which offers the possibility of complex assessment of the condition, including the prognosis.

References

Diaconu A, Coculescu BI, Manole G, Vultur H, Coculescu EC, Stocheci CM, Tudorache IS, Dincă AL, Dincă GV. Lipoprotein-associated phospholipase A2 (Lp-PLA2) - possible diagnostic and risk biomarker in chronic ischemic heart disease, J Enzyme Inhib Med Chem 2021; 36(1): 68- 73. https://doi.org/10.1080/14756366.2020.1839447

Coculescu BI, Manole G, Dincă GV, Coculescu EC, Berteanu C, Stocheci CM. Osteopontin - a biomarker of disease, but also of stage stratification of the functional myocardial contractile deficit by chronic ischaemic heart disease, J Enzyme Inhib Med Chem 2019; 34(1): 783-788. https://doi.org/10.1080/14756366.2019.1587418

Coculescu BI, Dincă GV, Bălăeţ C, Manole G, Bălăeţ M, Stocheci CM, Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction, J Enzyme Inhib Med Chem 2018; 33(1): 1292-1298. https://doi.org/10.1080/14756366.2018.1499626

Coculescu BI, Dincă GV, Manole G, Purcărea VL, Oproiu AM, Stocheci CM. Serum concentration of hsCRP - possible marker for therapy evaluation in left ventricular dysfunction with preserved ejection fraction, Rev de Chimie (Bucharest) 2018; 69(10): 2885-2890. https://doi.org/10.37358/RC.18.10.6646

Coculescu BI, Manole G, Dinca AL, Harsovescu T, Tudorache IS. The possible serum complex-biomarkers for the early diagnosis of diastolic dysfunction with preserved systolic function, Rev. de Chimie (Bucharest) 2019; 70(6): 2229-2231. https://doi.org/10.37358/RC.19.6.7311

Coculescu BI, Harsovescu T, Tudorache IS, Manole G. PON- 1, possible biomarker for diagnosis but also for risk in diastolic dysfunction with preserved ejection fraction, Rev. de Chimie (Bucharest) 2019; 70(4): 1210-1214. https://doi.org/10.37358/RC.19.4.7093

Tudorache SI, Coculescu BI, Manole G, Harsovescu T, Tone MB, Dinca AL. Myeloperoxidase (MPO), possible biomarker in heart failure, Rev. de Chimie (Bucharest), 2019; 70(6): 2173-2176. https://doi.org/10.37358/RC.19.6.7299

Coculescu BI, Dincă GV, Manole G. A novel biomarker in diastolic dysfunction with preserved ejection fraction, Mædica - a Journal of Clinical Medicine, 2019; 14(Suppl): 39.

Coculescu BI, Dincă GV, Manole G. Clinico-biological significance of serum myeloperoxidase in diastolic dysfunction with preserved ejection fraction, 24th Congress of Balkan Military Medical Committee (BMMC), 30 April - 3 May 2019, Tirana, Albania.

Downloads

Published

2022-06-03

How to Cite

Coculescu, B.-I., Dincă, G. V., Manole, G., & Coculescu, E. C. (2022). Identification of Possible Biomarkers in Cardiovascular Diseases. Journal of Hematology Research, 9, 1–3. https://doi.org/10.12974/2312-5411.2022.09.01

Issue

Section

Articles